These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26153084)

  • 1. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy.
    Tomaz PR; Santos JR; Issa JS; Abe TO; Gaya PV; Krieger JE; Pereira AC; Santos PC
    Eur J Clin Pharmacol; 2015 Sep; 71(9):1067-73. PubMed ID: 26153084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 2A6 and 2B6 polymorphisms and smoking cessation success in patients treated with varenicline.
    Tomaz PRX; Kajita MS; Santos JR; Scholz J; Abe TO; Gaya PV; Krieger JE; Pereira AC; Santos PCJL
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1541-1545. PubMed ID: 31402421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.
    Lee AM; Jepson C; Hoffmann E; Epstein L; Hawk LW; Lerman C; Tyndale RF
    Biol Psychiatry; 2007 Sep; 62(6):635-41. PubMed ID: 17223085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women.
    Tomaz PRX; Santos JR; Scholz J; Abe TO; Gaya PV; Negrão AB; Krieger JE; Pereira AC; Santos PCJL
    BMC Med Genet; 2018 Apr; 19(1):55. PubMed ID: 29621993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.
    David SP; Brown RA; Papandonatos GD; Kahler CW; Lloyd-Richardson EE; Munafò MR; Shields PG; Lerman C; Strong D; McCaffery J; Niaura R
    Nicotine Tob Res; 2007 Aug; 9(8):821-33. PubMed ID: 17654295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy.
    Rocha Santos J; Tomaz PR; Issa JS; Abe TO; Krieger JE; Pereira AC; Santos PC
    Front Genet; 2015; 6():46. PubMed ID: 25774163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.
    Cox LS; Faseru B; Mayo MS; Krebill R; Snow TS; Bronars CA; Nollen NL; Choi WS; Okuyemi KS; Salzman GA; Benowitz NL; Tyndale RF; Ahluwalia JS
    Trials; 2011 Jan; 12():22. PubMed ID: 21266057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2B6 gene single-nucleotide polymorphisms in an Italian population sample and relationship with nicotine dependence.
    Riccardi LN; Carano F; Bini C; Ceccardi S; Ferri G; Pelotti S
    Genet Test Mol Biomarkers; 2015 Feb; 19(2):103-7. PubMed ID: 25489907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective association of dopamine-related polymorphisms with smoking cessation in general care.
    Breitling LP; Twardella D; Hoffmann MM; Witt SH; Treutlein J; Brenner H
    Pharmacogenomics; 2010 Apr; 11(4):527-36. PubMed ID: 20350135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
    Lerman C; Jepson C; Wileyto EP; Epstein LH; Rukstalis M; Patterson F; Kaufmann V; Restine S; Hawk L; Niaura R; Berrettini W
    Neuropsychopharmacology; 2006 Jan; 31(1):231-42. PubMed ID: 16123753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.
    David SP; Strong DR; Leventhal AM; Lancaster MA; McGeary JE; Munafò MR; Bergen AW; Swan GE; Benowitz NL; Tyndale RF; Conti DV; Brown RA; Lerman C; Niaura R
    Addiction; 2013 Dec; 108(12):2202-11. PubMed ID: 23941313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abstinence rates and predictors of outcome for smoking cessation: do Brazilian smokers need special strategies?
    Chatkin JM; Mariante de Abreu C; Haggsträm FM; Wagner MB; Fritscher CC
    Addiction; 2004 Jun; 99(6):778-84. PubMed ID: 15139876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation.
    Yang M; Chen H; Johnson ML; Essien EJ; Peters RJ; Wang X; Abughosh S
    Subst Use Misuse; 2016; 51(5):586-97. PubMed ID: 27007975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic investigation of smoking cessation treatment.
    Lerman C; Shields PG; Wileyto EP; Audrain J; Pinto A; Hawk L; Krishnan S; Niaura R; Epstein L
    Pharmacogenetics; 2002 Nov; 12(8):627-34. PubMed ID: 12439223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking Cessation Pharmacotherapy Based on Genetically-Informed Biomarkers: What is the Evidence?
    Panagiotou OA; Schuit E; Munafò MR; Bennett DA; Bergen AW; David SP
    Nicotine Tob Res; 2019 Aug; 21(9):1289-1293. PubMed ID: 30690475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking cessation treatment among dually diagnosed individuals: preliminary evaluation of different pharmacotherapies.
    Saxon AJ; Baer JS; Davis TM; Sloan KL; Malte CA; Fitzgibbons K; Kivlahan DR
    Nicotine Tob Res; 2003 Aug; 5(4):589-96. PubMed ID: 12959797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CYP2B6 pharmacogenomics in bupropion-mediated smoking cessation.
    Tran AX; Ho TT; Varghese Gupta S
    J Clin Pharm Ther; 2019 Apr; 44(2):174-179. PubMed ID: 30578565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between DRD2/ANKK1 Taq1A genotypes, depression and smoking cessation with nicotine replacement therapy.
    Stapleton JA; Sutherland G; O'Gara C; Spirling LI; Ball D
    Pharmacogenet Genomics; 2011 Aug; 21(8):447-53. PubMed ID: 21540761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
    Lv J; Hu L; Zhuo W; Zhang C; Zhou H; Fan L
    Pharmacogenet Genomics; 2016 Feb; 26(2):80-7. PubMed ID: 26580670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes.
    Bloom AJ; Martinez M; Chen LS; Bierut LJ; Murphy SE; Goate A
    PLoS One; 2013; 8(11):e79700. PubMed ID: 24260284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.